Terns Pharmaceuticals TERN

$ 8.55 -3.39%

Quarterly report 2024-Q2
added 08-05-2024

Terns Pharmaceuticals Balance Sheet 2011-2024 | TERN

Annual Balance Sheet Terns Pharmaceuticals

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-142 M	-	-62 M	-12.3 M	-82.5 M	-	-	-	-	-	-	-
Long Term Debt	-	544 K	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	603 K	661 K	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	877 K	14.7 M	14.5 M	-	-	-	-	-	-	-
Total Current Liabilities	11.9 M	8.47 M	6.82 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	13.2 M	10.1 M	7.77 M	23.7 M	19.7 M	16.8 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	836 K	-	-	-	-	-	-	-	-	-
Retained Earnings	-333 M	-242 M	-182 M	-132 M	-91.9 M	-23.3 M	-	-	-	-	-	-	-
Total Assets	269 M	287 M	168 M	92.3 M	23.9 M	89.1 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	79.9 M	143 M	47.7 M	-	-	-	-	-	-	-	-	-	-
Book Value	255 M	277 M	160 M	68.6 M	4.21 M	72.2 M	-	-	-	-	-	-	-
Total Shareholders Equity	255 M	277 M	160 M	-117 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Terns Pharmaceuticals

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	63 K	223 K	386 K	544 K	702 K	851 K	1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	12.2 M	10 M	13.2 M	13.3 M	15.5 M	13.6 M	10.1 M	8.89 M	7.64 M	7.95 M	7.77 M	7.73 M	6.68 M	9.24 M	23.7 M	23.7 M	23.7 M	23.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-378 M	-355 M	-333 M	-312 M	-282 M	-264 M	-242 M	-227 M	-210 M	-196 M	-182 M	-168 M	-156 M	-145 M	-132 M	-132 M	-132 M	-132 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	231 M	247 M	269 M	272 M	290 M	301 M	287 M	193 M	145 M	157 M	168 M	180 M	188 M	199 M	92.3 M	92.3 M	92.3 M	92.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	91.5 M	65.1 M	79.9 M	37.9 M	80.9 M	184 M	143 M	63 M	16.8 M	43.9 M	47.7 M	64.8 M	67.6 M	98.8 M	74.9 M	74.9 M	74.9 M	74.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	219 M	237 M	255 M	258 M	274 M	288 M	277 M	184 M	137 M	149 M	160 M	172 M	181 M	190 M	68.6 M	68.6 M	68.6 M	68.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	219 M	237 M	255 M	258 M	274 M	288 M	277 M	184 M	137 M	149 M	160 M	172 M	181 M	190 M	-117 M	-117 M	-117 M	-117 M	-90.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency